MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.15

-0.3%

Nov 3 1:15 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (2055)	9/11/2008 8:09:34 AM
From: Icebrg	of 2240

Ahead of the Bell: Medarex downgraded Thursday September 11, 7:44 am ET Analyst doesn't expect melanoma drug ipilimumab's primary data until late '09, launch in '10 NEW YORK (AP) -- A JPMorgan analyst downgraded shares of Medarex Inc. Thursday, saying the stock will trade in place until the second half of 2009, when Medarex reports critical late-stage trial data for its melanoma drug candidate ipilimumab. Matthew Roden said mid-stage data for the drug was not very strong, and he thinks investors will wait for late-stage data that proves ipilimumab is effective as a primary treatment for advanced melanoma. Until that time, he expects the stock to trade only at the value of Medarex's cash and royalties. Roden cut his rating to "Neutral" from "Overweight." Previously, he said, he expected strategic alternatives or more developments from the Princeton, N.J., company's pipeline. He now expects ipilimumab to reach the market in late 2010. Medarex is developing the drug in a partnership with Bristol-Myers Squibb Co. It is designed to treat advanced metastatic melanoma, a deadly type of skin cancer. Medarex shares finished at $6.95 Wednesday, and have traded between $6.41 and $15.69 over the past year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next